Blockchain Registration Transaction Record

New Breast Cancer Biomarker Predicts Chemo & Immunotherapy Success

University of Illinois researchers discover FGD3 protein biomarker that predicts breast cancer patients' response to chemotherapy and immunotherapy treatments, advancing precision medicine.

This discovery represents a significant advancement in personalized cancer care, potentially transforming treatment outcomes for breast cancer patients. By identifying which patients will respond to chemotherapy and immunotherapy, doctors can avoid subjecting non-responsive patients to unnecessary treatments with severe side effects, while ensuring responsive patients receive the most effective therapies sooner. This biomarker could lead to more targeted treatment approaches, reduced healthcare costs, improved quality of life during treatment, and better survival rates. For the broader medical community and pharmaceutical companies, it opens new avenues for developing more precise cancer therapies and advancing the field of precision oncology.